TD Cowen analyst Ritu Baral has maintained their bullish stance on PVLA stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ritu Baral’s rating is based on Palvella Therapeutics’ strategic decision to expand the clinical applications of its QTORIN rapamycin product, specifically targeting clinically significant angiokeratoma (CSA). This new indication addresses a high unmet medical need, as there are currently no FDA-approved treatments for CSA, and existing options are invasive and often inadequate.
The company’s proprietary research indicates a strong market potential, with a significant number of physicians expressing interest in adopting an approved topical rapamycin treatment. Additionally, Palvella’s established formulation and regulatory rapport with the FDA are expected to expedite the clinical development process, enhancing the value of QTORIN rapamycin as a versatile therapeutic product. These factors collectively support the Buy rating given by Ritu Baral.
According to TipRanks, Baral is a 5-star analyst with an average return of 18.7% and a 52.92% success rate. Baral covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Krystal Biotech, and ACADIA Pharmaceuticals.
In another report released yesterday, Stifel Nicolaus also reiterated a Buy rating on the stock with a $80.00 price target.